Seeking Alpha

KaloBios Pharmaceuticals slips on a Q2 miss

  • KaloBios Pharmaceuticals (KBIO -2.3%) slips after its Q2 loss came in greater than Street expectations.
  • The company attributes the loss to increased spending for clinical trial programs and higher SG&A expenses associated with being a public company.
  • Contract revenues were $15K, down from the prior-year period's $2.99M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector